Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 25Pancreatic Neoplasms 19Neoplasm Metastasis 17Neuroblastoma 8Lung Neoplasms 6Rhabdomyosarcoma 5Rectal Neoplasms 5Neoplasms 5Esophageal Squamous Cell Carcinoma 5Colonic Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma, Ewing 4Sarcoma 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Wilms Tumor 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Kidney Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Glioma 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adult Solid Neoplasm × Irinotecan × 90 days × Clear all
NCT00045201 2026-04-13

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
60 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡